MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-30-2026
Sangamo Therapeutics ROA Ratio 2011-2026 | SGMO
Annual ROA Ratio Sangamo Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -205.76 | -96.37 | -155.96 | -34.18 | -24.7 | -12.89 | -14.93 | -11.57 | -19.03 | -45.38 | -18.74 | -10.86 | -18.9 | -26.98 | -40.93 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -10.86 | -205.76 | -49.15 |
Quarterly ROA Ratio Sangamo Therapeutics
| 2025-Q3 | 2025-Q2 | 2024-Q3 | 2024-Q2 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -89.14 | -97.15 | -111.89 | -116.68 | -86.79 | -48.33 | -19.82 | -22.39 | -28.57 | -19.07 | -24.72 | -17.06 | -21.38 | -15.37 | -13.56 | -12.89 | -7.85 | -11.97 | -12.89 | -14.93 | -18.81 | -16.7 | -14.77 | -11.57 | -12.98 | -15.11 | -16.65 | -19.03 | -20.56 | -28.26 | -40.74 | -45.38 | -45.74 | -37.98 | -26.73 | -18.74 | -14.06 | -12.91 | -10.2 | -10.86 | -14.87 | -16.13 | -17.13 | -18.9 | -17.34 | -19.99 | -23.06 | -26.98 | -30.04 | -33.97 | -38.77 | -40.93 | -10.94 | -11.75 | -10.97 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -7.85 | -116.68 | -28.4 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
Grifols, S.A.
GRFS
|
1.38 | $ 8.24 | -0.12 % | $ 6.83 B |  Spain |
 |
Ascendis Pharma A/S
ASND
|
-35.36 | $ 229.25 | 0.44 % | $ 5 B |  Danmark |
 |
I-Mab
IMAB
|
7.43 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B |  USA |
 |
Genfit SA
GNFT
|
23.87 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M | France |
 |
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
AbbVie
ABBV
|
1.36 | $ 208.84 | -2.86 % | $ 369 B | USA |
 |
AbCellera Biologics
ABCL
|
-10.79 | $ 3.52 | 0.28 % | $ 1.05 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
-232.99 | - | -24.86 % | $ 820 K | USA |
 |
Adverum Biotechnologies
ADVM
|
-72.8 | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | USA |
 |
Applied Molecular Transport
AMTI
|
-117.57 | - | - | $ 10.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-275.96 | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
-19.87 | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
-1.36 | $ 3.33 | -2.06 % | $ 99 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-31.09 | - | 0.23 % | $ 488 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Allena Pharmaceuticals
ALNA
|
-140.01 | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-20.15 | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-206.44 | - | 10.36 % | $ 9.8 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-11.6 | $ 14.81 | 2.63 % | $ 2.25 B | USA |
 |
Altimmune
ALT
|
-31.47 | $ 3.34 | 7.05 % | $ 294 M | USA |
 |
BioNTech SE
BNTX
|
65.02 | $ 91.18 | 1.97 % | $ 27.2 B | Germany |
 |
Amgen
AMGN
|
8.51 | $ 347.94 | -1.51 % | $ 187 B | USA |
 |
ANI Pharmaceuticals
ANIP
|
-1.44 | $ 74.21 | -2.3 % | $ 1.43 B | USA |
 |
Aravive
ARAV
|
-122.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-24.26 | $ 8.03 | 2.29 % | $ 220 M |  Israel |
 |
Aptose Biosciences
APTO
|
-254.37 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aurinia Pharmaceuticals
AUPH
|
28.05 | $ 15.61 | 0.9 % | $ 2.1 B | Canada |
 |
Autolus Therapeutics plc
AUTL
|
-48.81 | $ 1.41 | 2.17 % | $ 375 M | Britain |
 |
Aptinyx
APTX
|
-97.25 | - | -39.0 % | $ 4.57 M | USA |
 |
Aytu BioScience
AYTU
|
-10.92 | $ 2.68 | 1.52 % | $ 16.8 M | USA |
 |
CureVac N.V.
CVAC
|
-35.55 | - | - | $ 867 M | Germany |
 |
AstraZeneca PLC
AZN
|
0.11 | - | - | $ 96.9 B | Britain |
 |
Burford Capital Limited
BUR
|
5.51 | $ 4.14 | -2.59 % | $ 683 M | Britain |
 |
Avenue Therapeutics
ATXI
|
-99.25 | - | -52.27 % | $ 4.45 M | USA |
 |
Atea Pharmaceuticals
AVIR
|
-50.23 | $ 5.76 | 1.95 % | $ 469 M | USA |
 |
AVROBIO
AVRO
|
12.03 | - | 1083.1 % | $ 745 M | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
-18.12 | $ 9.02 | -3.84 % | $ 1.86 B | USA |
 |
Axcella Health
AXLA
|
-428.94 | - | -16.42 % | $ 249 M | USA |
 |
Axon Enterprise
AXON
|
8.43 | $ 412.81 | -2.54 % | $ 31.3 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
6.32 | $ 318.85 | -3.01 % | $ 41.8 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-489.29 | - | - | $ 7.46 M | Israel |